Tilray Brands (TLRY) Cash from Investing Activities Growth (1y) (2018 - 2026)
Tilray Brands (TLRY) Cash from Investing Activities Growth (1y) (2018 - 2026) Analysis & Trends
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.15 Bn | 39.49 Bn | 2.15 Bn | -308.05% |
| 3 | Zoetis | 31.52 Bn | 29.84 Bn | 1.05 Bn | -41.51% |
| 4 | Takeda Pharmaceutical | 28.58 Bn | 22.78 Bn | 5.10 Bn | -139.86% |
| 5 | United Therapeutics | 22.16 Bn | 19.50 Bn | 683.80 Mn | 129.18% |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn | 1.71% |
| 7 | Neurocrine Biosciences | 15.48 Bn | 15.09 Bn | 935.80 Mn | -366.90% |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | -96.43% |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | - |
| 10 | Tilray Brands | 516.11 Mn | 281.48 Mn | 90.52 Mn | -478.51% |
Historic Data
Download Data| Date | Value |
|---|---|
| May 31, 2026 | -478.51% |
| Feb 28, 2026 | 24,400.00% |
| Nov 30, 2025 | -440.84% |
| Aug 31, 2025 | 149.53% |
| May 31, 2025 | -69.99% |
| Feb 28, 2025 | -100.42% |
| Nov 30, 2024 | -113.16% |
| Aug 31, 2024 | -87.89% |
| May 31, 2024 | 694.09% |
| Feb 29, 2024 | 711.63% |
| Nov 30, 2023 | 130.03% |
| Aug 31, 2023 | -1,610.47% |
| May 31, 2023 | -54.30% |
| Feb 28, 2023 | -347.56% |
| Nov 30, 2022 | -3,792.69% |
| Aug 31, 2022 | 82.17% |
| May 31, 2022 | -101.41% |
| Nov 30, 2021 | 97.52% |
| Aug 31, 2021 | 37.07% |
| May 31, 2021 | 79.16% |